Skip to Content

Briviact Approval History

  • FDA approved: Yes (First approved February 19th, 2016)
  • Brand name: Briviact
  • Generic name: brivaracetam
  • Company: UCB, Inc.
  • Treatment for: Epilepsy

Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.

Development History and FDA Approval Process for Briviact

May 14, 2018Approval UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients
Sep 15, 2017Approval FDA Approves New indication for Briviact (brivaracetam) as Monotherapy Treatment of Partial-Onset Seizures in Adults
Feb 19, 2016Approval FDA Approves Briviact (brivaracetam) to Treat Partial Onset Seizures
Jan 21, 2015UCB Announces US and EU Regulatory Filings for the Investigational Antiepileptic Drug Brivaracetam
Dec  8, 2014Data from Phase 3 Study Evaluating Brivaracetam as Adjunctive Treatment of Partial-Onset Seizures

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.